Atea Pharmaceuticals: The U.S. FDA Granted Fast Track Designation to Bemnifosbuvir Oral Antiviral for COVID-19

Atea Pharmaceuticals Receives Fast Track Designation for Bemnifosbuvir

Atea Pharmaceuticals (AVIR) announced that the U.S. FDA has granted Fast Track designation to its product bemnifosbuvir for the treatment of resistant COVID-19.  

Bemnifosbuvir is an oral, direct acting antiviral drug candidate being evaluated in the global Phase 3 SUNRISE-3 registrational trial for the treatment of COVID . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.